Elevance Health, Inc.
AI Company Overview
AI-written background, not sourced to filings. Treat any figure here as unverified; the sections below link to the government records.
Elevance Health is a leading U.S. health insurer and integrated healthcare services company, offering commercial, Medicare, and Medicaid plans alongside pharmacy, behavioral, and clinical solutions.
-
Executive Summary: Elevance Health, Inc. (formerly Anthem, Inc.) is a Fortune 500 health benefits company that provides a spectrum of medical, digital, pharmacy, behavioral, and clinical services. It serves over 47 million medical members through affiliated Blue Cross and Blue Shield plans in 14 states and a broad portfolio of managed care solutions for government and commercial clients, aiming to be a lifetime, trusted health partner.
-
Government Reliance & Contracts: Elevance Health has significant reliance on federal and state government healthcare programs. Key contracts include:
- Medicaid Managed Care: Serves millions of low-income individuals and families through contracts with state Medicaid agencies across its Blue plan states.
- Medicare Advantage: Offers Medicare Advantage prescription drug plans and standalone Part D plans, with CMS reimbursement.
- Federal Employee Program (FEP): Administers the Blue Cross and Blue Shield Service Benefit Plan for federal employees, retirees, and their families, under contract with the U.S. Office of Personnel Management (OPM).
- Department of Defense: Provides TRICARE benefits as a subcontractor in certain regions. Overall, government-sponsored programs account for a substantial portion of its revenue (over 60% historically), making the company highly sensitive to policy changes and reimbursement rates.
- Moats & Key Technology:
- Regulatory & Brand Moat: Exclusive Blue Cross and Blue Shield licenses in 14 states, granting strong brand recognition, large provider networks, and high member retention.
- Scale & Data: Unmatched claims and clinical data from 100+ million members enable advanced analytics, risk stratification, and personalized care models.
- Technology Platforms: Carelon (its health services arm) integrates PBM (IngenioRx), behavioral health (Beacon), and complex care management, using AI-driven tools for care coordination, utilization management, and digital engagement. Investments in cloud-native platforms and interoperability drive efficiency and member experience.
- Patents: Holds numerous patents in predictive analytics, care navigation, and fraud detection (e.g., US patents for machine learning-based clinical decision support).
-
Capital & Shadow Backers: As a publicly traded company (NYSE: ELV), Elevance Health’s largest shareholders are institutional investors such as The Vanguard Group (approx. 9%), BlackRock (approx. 7%), and State Street. Originally part of the Blue Cross Blue Shield system, the company demutualized and went public as Anthem, Inc. in 2001. In 2022, it rebranded to Elevance Health to reflect its evolution beyond traditional insurance. There are no dominant private equity or venture capital backers.
-
Recent Catalysts:
- Medicaid Redeterminations: The unwinding of continuous enrollment post-COVID has led to membership losses in Medicaid, partly offset by growth in ACA marketplace and commercial segments.
- Carelon Expansion: Aggressive diversification into healthcare services (pharmacy, behavioral health, post-acute care) to generate higher-margin revenue and reduce cyclicality.
- Medicare Advantage Growth: Continued investment in MA plan benefits and star ratings, with expectations of long-term demographic tailwinds.
- Regulatory and Legislative Environment: Scrutiny of PBM practices, drug pricing reforms (Inflation Reduction Act), and MA payment rates are key watchpoints.
- Share Repurchases & Dividends: Strong capital return program underscores confidence in cash flow generation.
- Digital Health M&A: Acquired companies like myNEXUS (home health management) and Integra Managed Care to enhance post-acute capabilities, signaling a deeper push into value-based care.
Government Contracts & Awards
Proprietary Tech & Patents
No patents found in our USPTO sample (a narrow, keyword-clustered feed of recent grants in strategic tech sectors — not a comprehensive patent database).
Form D Funding
No recent SEC Form D filings found.
Market Intelligence & News
Should You Buy Elevance Health Stock For The Margin It Lost?
Elevance Health (ELV) has returned more than 40% over the past six months, though it is down 6.5% over the past three while the S&P 500 gained 3.4%. The next leg will not come from selling more insurance. It will come from keeping more of the premium it already collects.
The Hidden Engine Behind Elevance Health Stock's Next Climb
Investors are rightly focused on the company's Medicaid struggles, but the real upside story may be hiding in plain sight across the rest of its business.
What's A Strong Quarter Worth When Elevance Health Is Ditching Its Own Markets?
The health insurer raised its forecast after a solid quarter, but investors focused on the one business so broken it’s forcing a strategic retreat.
Cantor Fitzgerald Maintains Overweight on Elevance Health, Raises Price Target to $450
Cantor Fitzgerald analyst Sarah James maintains Elevance Health (NYSE:ELV) with a Overweight and raises the price target from $400 to $450.
Elevance Health to Hold Conference Call and Webcast to Discuss Second Quarter 2026 Results on July 15, 2026
INDIANAPOLIS, July 06, 2026--Elevance Health (NYSE: ELV) will release second quarter 2026 financial results on July 15, 2026, at 6:00 a.m. Eastern Daylight Time ("EDT"). Management will review these results and its outlook during a conference call at 8:30 a.m. EDT that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:
Elevance Health (ELV) Sues CMS Over Medicare Ratings And Lost Bonus Payments
Elevance Health (NYSE:ELV) has filed a lawsuit against the Centers for Medicare & Medicaid Services over how Medicare Advantage star ratings were recalculated. The company argues CMS used different processes for Elevance compared with Clover Health, which it says led to a substantial loss of bonus payments. The dispute centers on regulatory consistency and could influence how quality scores and related payments are handled for Medicare insurers. For investors tracking Elevance Health, the...
Can Elevance Health (ELV) Stay Below Fair Value After A 23% Gain?
After a solid 22.7% 1 year return, Elevance Health is trading with valuation checks that still lean supportive. The question for investors is whether the recent share price strength has already captured most of the upside or not. Over the past year, Elevance Health has returned 22.7%, which puts recent gains front and center when judging how much value may be left on the table. On the fundamentals side, ongoing investments in platforms like Health OS can support earnings power, while...
The Unpopular Move That Telegraphed the Elevance Health Stock Surge
While Wall Street fixated on a gloomy forecast, the company was making a painful but telling choice that hinted at the turnaround to come.
Elevance Health (ELV) Enhances Health OS to Automate Clinical Reviews and Reduce Provider Administrative Burdens
Elevance Health Inc. (NYSE:ELV) is one of the best value stocks to buy right now. On June 23, Elevance Health announced enhancements to Health OS, a secure platform that streamlines clinical reviews by integrating directly with electronic health records. By replacing manual processes with automated data sharing, the system significantly reduces administrative burdens for providers, […]
2 Reasons to Like ELV (and 1 Not So Much)
Elevance Health has had an impressive run over the past six months as its shares have beaten the S&P 500 by 6.8%. The stock now trades at $395.55, marking a 13.5% gain. This was partly thanks to its solid quarterly results, and the performance may have investors wondering how to approach the situation.
Congressional Trades in $ELV
Insider Trades (Form 4)
Wessling Erin M
Craig Ryan R
BOUDREAUX GAIL
PERU RAMIRO G
Penczek Ronald W
Dixon Robert L JR
Penczek Ronald W
PERU RAMIRO G
Key People
BOUDREAUX GAIL
President and CEO
PERU RAMIRO G
Director
Kendrick Charles Morgan
EVP & President, Commercial
COLLIS STEVEN H
Director
Political Giving
$642,042 given to 107 candidates across 310 disclosed contributions (FEC Schedule A).
James E Hon Banks
Bradley S. Schneider
Suzan K. DelBene
Terri A. Sewell
Katherine M. Clark
Linda T. Sanchez
Kevin Hern
Adrian Smith
Josh Gottheimer
Virginia Foxx
Jefferson Shreve
Greg Steube
Jared Moskowitz
Jennifer McClellan
Scott H. Peters
Laurel Lee
John Curtis
Thomas Suozzi
Cliff Bentz
Max Miller
+ 87 more recipients not shown.
Factual Connections
Connections to other companies, executives, and politicians — sourced from disclosed trades, shared officers/directors, and public filings — are a Pro/Alpha feature.
Upgrade to Pro